Axsome Therapeutics (AXSM) Inventory Average (2022 - 2026)

Axsome Therapeutics (AXSM) has 5 years of Inventory Average data on file, last reported at $29.7 million in Q1 2026.

• For the quarter ending Q1 2026, Inventory Average rose 85.49% year-over-year to $29.7 million; the trailing twelve-month figure through Mar 2026 stood at $29.7 million (up 85.49% YoY), and the FY2025 full-year result was $21.8 million, up 41.48% from the prior year.
• Inventory Average grew to $29.7 million in Q1 2026, from $25.9 million in the prior quarter.
• In the past five years, Inventory Average ranged from a high of $29.7 million in Q1 2026 to a low of $6.1 million in Q1 2023.
• A 5-year average of $16.0 million and a median of $15.0 million in 2024 frame the typical range for Inventory Average.
• Across the five-year window, Inventory Average soared 240.23% in 2024 and declined 23.16% in 2025, its largest moves.
• Tracing AXSM's Inventory Average over 5 years: stood at $9.2 million in 2022, then jumped by 37.21% to $12.6 million in 2023, then climbed by 19.41% to $15.0 million in 2024, then surged by 72.39% to $25.9 million in 2025, then rose by 14.97% to $29.7 million in 2026.
• Business Quant data shows AXSM's Inventory Average at $29.7 million in Q1 2026, $25.9 million in Q4 2025, and $21.1 million in Q3 2025.